Maryland Clinical Trials Report — June 2026

For Maryland residents considering participation in clinical research, June 2026 presents a dynamic landscape of new opportunities alongside a critical window for trials nearing their conclusion. Across the state, 151 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 37 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on stroke, various cancers, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stroke
• Breast cancer
• Opioid use disorder
• Pancreatic cancer
• Mild cognitive impairment
• Cardiovascular disease
• HIV
• Prostate cancer
• Depression
• Mesothelioma

New Research Initiatives Launch Across Maryland

This month, Maryland welcomes 47 new clinical trials, a notable increase from the 43 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity and type 2 diabetes, as well as crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy, safety, and tolerability of aleniglipron.
• Pfizer is leading an important Phase 3 vaccine trial: NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This trial aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants. Another AstraZeneca Phase 3 study, NCT07662213, will compare elecoglipron with oral semaglutide in 1,200 adults with type 2 diabetes and increased cardiovascular risk.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• A significant observational study, NCT07673016, is "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer," sponsored by Convergent Genomics, Inc., planning for 2,500 participants.
• The "Collaboration for Down Syndrome Progress (CDP)," NCT07625579, sponsored by RTI International, is a long-term study that follows 1,400 people with Down syndrome of all ages to better understand their health and development.

Expanding Research Across Conditions and Interventions

The 47 new trials opening this month in Maryland cover a diverse range of health conditions, with a strong focus on metabolic health and infectious disease prevention. The most common conditions addressed by these new studies include:

• Type 2 diabetes mellitus (4 trials)
• HIV (3 trials)
• Obesity (3 trials)
• Depression (2 trials)
• Pancreatic ductal adenocarcinoma (PDAC) (2 trials)
• Chronic weight management (2 trials)
• Migraine (2 trials)
• Overweight (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 29 of the new studies. Other types of research include devices, behavioral interventions, dietary supplements, and biological treatments.

Notable sponsors driving these new initiatives include AstraZeneca with 7 new trials, Johns Hopkins University with 4, and the National Cancer Institute (NCI) with 3. Overall, industry sponsors are behind 23 of the new trials, while NIH-funded research accounts for 9, and academic institutions contribute significantly.

Geographic Reach: Baltimore Leads, Statewide Access Continues

Maryland's clinical research landscape continues to be robust, with 2,552 clinical trials currently recruiting across 86 cities and 1,096 research sites statewide. This month, the majority of new research initiatives are concentrated in the Baltimore metropolitan area, which saw 20 new trials open. However, opportunities are also expanding in other parts of the state:

• Bethesda (9 new trials)
• Rockville (6 new trials)
• Silver Spring (3 new trials)
• Potomac (2 new trials)
• Lutherville-Timonium (2 new trials)
• Pikesville (2 new trials)
• Brooklyn (1 new trial)
• Columbia (1 new trial)
• Bowie (1 new trial)

This distribution ensures that residents in various regions of Maryland have access to cutting-edge research, even as major cities remain central hubs for clinical investigations.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 47 new trials launched this month, 7 are actively seeking healthy volunteers. Statewide, a total of 531 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Maryland are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 5 include children as participants, and 43 include older adults, ensuring that research benefits diverse age groups. Additionally, 1 new trial is specifically for female participants, and 1 is for male participants, addressing gender-specific health questions.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Maryland.